Soo Yeun Lee

Dr. Soo Yeun Lee

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Polymers
Verified
Journal Article
Open access
PDF file
SKSUJIN KANG
SUJIN KANG
SLSoo Yeun Lee
Soo Yeun Lee
SPSoyeun Park
Soyeun Park
The unique structure and physiology of a tumor microenvironment impede intra-tumoral penetration of chemotherapeutic agents. A novel iRGD peptide that exploits the tumor microenvironment can activate integrin-dependent binding to tumor vasculatures and neuropilin-1 (NRP-1)-dependent transport to tumor tissues. Recent studies have focused on its dual-targeting ability to achieve enhanced penetration of chemotherapeutics for the efficient eradication of cancer cells. Both the covalent conjugation and the co-administration of iRGD with chemotherapeutic agents and engineered delivery vehicles have been explored. Interestingly, the iRGD-mediated drug delivery also enhances penetration through the blood–brain barrier (BBB). Recent studies have shown its synergistic effect with BBB disruptive techniques. The efficacy of immunotherapy involving immune checkpoint blockades has also been amplified by using iRGD as a targeting moiety. In this review, we presented the recent advances in iRGD technology, focusing on cancer treatment modalities, including the current clinical trials using iRGD. The iRGD-mediated nano-carrier system could serve as a promising strategy in drug delivery to the deeper tumor regions, and be combined with various therapeutic interventions due to its novel targeting ability.

6 April 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
NKNikita Katila
Nikita Katila
RDRamesh Duwa
Ramesh Duwa
SBSunil Bhurtel
Sunil Bhurtel
SKShristi Khanal
Shristi Khanal
SMSrijan Maharjan
Srijan Maharjan
SYSIMMYUNG YOOK
SIMMYUNG YOOK

1 June 2016 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MKMinjeong Kim
Minjeong Kim
JLJin-Gyeom Lee
Jin-Gyeom Lee
CYChae Ha Yang
Chae Ha Yang
SLSoo Yeun Lee
Soo Yeun Lee

1 February 2014 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JKJihyun Kim
Jihyun Kim
DJDajeong Ji
Dajeong Ji
SKSoyoung Kang
Soyoung Kang
MPMeejung Park
Meejung Park
WYWonkyung Yang
Wonkyung Yang
SLSoo Yeun Lee
Soo Yeun Lee

12 June 2019 in Molecules
Verified
Journal Article
Open access
PDF file
WJWon-Jun Jang
Won-Jun Jang
JCJae Yoon Choi
Jae Yoon Choi
BPByoungduck Park
Byoungduck Park
JSJi Hae Seo
Ji Hae Seo
YSYoung Ho Seo
Young Ho Seo
SLSoo Yeun Lee
Soo Yeun Lee
Metabolomics is a powerful tool used to understand comprehensive changes in the metabolic response and to study the phenotype of an organism by instrumental analysis. It most commonly involves mass spectrometry followed by data mining and metabolite assignment. For the last few decades, hair has been used as a valuable analytical sample to investigate retrospective xenobiotic exposure as it provides a wider window of detection than other biological samples such as saliva, plasma, and urine. Hair contains functional metabolomes such as amino acids and lipids. Moreover, segmental analysis of hair based on its growth rate can provide information on metabolic changes over time. Therefore, it has great potential as a metabolomics sample to monitor chronic diseases, including drug addiction or abnormal conditions. In the current review, the latest applications of hair metabolomics in animal studies and clinical settings are highlighted. For this purpose, we review and discuss the characteristics of hair as a metabolomics sample, the analytical techniques employed in hair metabolomics and the consequence of hair metabolome alterations in recent studies. Through this, the value of hair as an alternative biological sample in metabolomics is highlighted.

1 January 2017 in Oncology Reports
Verified
Journal Article
Open access
PDF file
DKDo-Hee Kim
Do-Hee Kim
JPJi Eun Park
Ji Eun Park
ICIn Gyeong Chae
In Gyeong Chae
GPGeumi Park
Geumi Park
SLSoo Yeun Lee
Soo Yeun Lee
Kyung-Soo ChunKyung-Soo Chun
Kyung-Soo Chun
Isoliquiritigenin (ISL) is a flavonoid with chalcone structure that has been noted in licorice and shallot, which are generally used in traditional Chinese medicine. ISL has demonstrated various pharmacological effects including antioxidant, anti-inflammatory and antitumor activity. However, the molecular mechanisms underlying the anticancer effects of ISL remain poorly understood. The present study revealed that ISL significantly decreased viability and induced apoptosis in human renal carcinoma Caki cells. The ISL-induced apoptosis was associated with the cleavage of caspase-9, -7 and -3, and that of PARP. Moreover, ISL increased the expression of pro-apoptotic protein Bax and diminished the expression of anti-apoptotic protein Bcl-2, and Bcl-xl, thereby increasing cytochrome c release. Treatment of cells with ISL also induced the expression of p53 through downregulation of murine double minute 2 (Mdm2). Furthermore, ISL generated reactive oxygen species (ROS), and pretreatment with ROS scavenger N-acetyl cysteine (NAC) and NADPH oxidase inhibitor diphenyleneiodonium abrogated the ISL-induced apoptosis. One of the key oncogenic signaling pathways is mediated through signal transducer and activator of transcription 3 (STAT3), which promotes abnormal cell proliferation. Incubation of cells with ISL markedly diminished phosphorylation and DNA binding activity of STAT3, and reduced expression of STAT3 responsive gene products, such as cyclin D1 and D2. ISL also attenuated constitutive phosphorylation of upstream kinase, Janus-activated kinase 2 (Jak2). Pretreatment with NAC abrogated the inhibitory effect of ISL on activation of STAT3 and blocked the cleavage of caspase-9, -7 and -3, and that of PARP in Caki cells. Taken together, the present study provides the first report that ISL induces apoptosis in Caki cells via generation of ROS, which causes induction of p53 and inhibition of the STAT3 signaling pathway.